Page 1 | Search Results | Blood | American Society of Hematology

1-20 of 47

Sort by

Sort Order Select

Journal Articles

A Single Center Retrospective Analysis of Daratumumab, Pomalidomide, and Dexamethasone As a Second Line Therapy for Multiple Myeloma

Lawrence Liu, MD, Gao Feng, MD PhD MPH, Mark A. Fiala, MSW, Justin King, BS, Scott R. Goldsmith, MD, Tanya M. Wildes, MD MSCI, Keith E. Stockerl-Goldstein, MD, Ravi Vij, MBBS, Mark A. Schroeder, MD

Blood (2020) 136 (Supplement 1): 31–32.

https://doi.org/10.1182/blood-2020-137023

Published: 2020

Journal Articles

Severity of Sars-Cov-2 Infection in Patients with Hematologic Malignancies: A COVID-19 and Cancer Consortium (CCC19) Registry Analysis

Samuel Rubinstein, MD, Ryan C. Lynch, MD, Aakash Desai, MD, Catherine Stratton, MPH, Alokkumar Jha, PhD, Ziad Bakouny, MD MSc, Andrew Schmidt, MD, R. Alejandro Sica, MD, Divaya Bhutani, MD, Dimpy P. Shah, MD PhD, Sarah A Wall, MD, Gary H. Lyman, MD, Nicole M. Kuderer, MD MSc, Matthias Weiss, MD PhD, Jeremy L. Warner, MD MS, Keith E. Stockerl-Goldstein, MD, Ruben Mesa, MD, Michael A. Thompson, MD PhD

Blood (2020) 136 (Supplement 1): 28–30.

https://doi.org/10.1182/blood-2020-141937

Published: 2020

Journal Articles

Preliminary Results from a Phase 1b Study of TAK-079, an Investigational Anti-CD38 Monoclonal Antibody (mAb) in Patients with Relapsed/ Refractory Multiple Myeloma (RRMM)

Amrita Y. Krishnan, MD, Krina K. Patel, MD MSc, Parameswaran Hari, MBBS, MD, Sundar Jagannath, MD, Ruben Niesvizky, MD, Rebecca W. Silbermann, MD, Deborah Berg, RN, MSN, Jianchang Lin, PhD, Eric Robert Fedyk, BSc, MSc, PhD, Antonio Palumbo, MD, Keith E. Stockerl-Goldstein, MD

Blood (2019) 134 (Supplement_1): 140.

https://doi.org/10.1182/blood-2019-128007

Published: 2019

Journal Articles

The Ire of IRE1α: Overexpression of IRE1α at Myeloma Diagnosis Is Associated with Decreased Survival While Downregulation of IRE1α Expression Is Predictive of Therapy Resistance

Scott R. Goldsmith, MD, Mark A. Fiala, BS, Mark A. Schroeder, MD, Tanya M. Wildes, MD, Armin Ghobadi, MD, Ravi Vij, MBBS, Keith E. Stockerl-Goldstein, MD

Blood (2019) 134 (Supplement_1): 4351.

https://doi.org/10.1182/blood-2019-131135

Published: 2019

Journal Articles

Utilization of Autologous Stem Cell Transplantation in Older Patients with Newly Diagnosed Multiple Myeloma

Justin King, Mark A. Fiala, BS, Scott R. Goldsmith, MD, Keith E. Stockerl-Goldstein, MD, Mark A. Schroeder, MD, Armin Ghobadi, MD, Ravi Vij, MBBS, Tanya M. Wildes, MD

Blood (2019) 134 (Supplement_1): 5701.

https://doi.org/10.1182/blood-2019-130689

Published: 2019

Journal Articles

The Characteristics, Treatment Patterns, and Outcomes of Older Adults with Multiple Myeloma

Mark A. Fiala, BS, Tanya M. Wildes, MD MSCI, Mark A. Schroeder, MD, Armin Ghobadi, MD, Keith E. Stockerl-Goldstein, MD, Ravi Vij, MBBS

Blood (2018) 132 (Supplement 1): 4463.

https://doi.org/10.1182/blood-2018-99-118660

Published: 2018

Journal Articles

The Effect of Maintenance Therapy Following Salvage Autologous Stem Cell Transplant in Multiple Myeloma Patients

Brandon B. Wang, Mark A. Fiala, BS, Mark A. Schroeder, MD, Tanya Wildes, MD, Armin Ghobadi, MD, Keith E. Stockerl-Goldstein, MD, Ravi Vij, MBBS

Blood (2018) 132 (Supplement 1): 3439.

https://doi.org/10.1182/blood-2018-99-111379

Published: 2018

Journal Articles

Increasing Daratumumab Frequency As a Way to Restore Responses- a Retrospective Case Study

Angela Vickroy, ANP, Adam Kent Peery, BS,ANP, Mark A. Fiala, BS, Tanya M. Wildes, MD MSCI, Mark A. Schroeder, MD, Armin Ghobadi, MD, Keith E. Stockerl-Goldstein, MD, Ravi Vij, MBBS

Blood (2018) 132 (Supplement 1): 5666.

https://doi.org/10.1182/blood-2018-99-119589

Published: 2018

Journal Articles

Bendamustine in Patients with Quad- and Penta-Refractory Multiple Myeloma

Scott Goldsmith, MD, Mark A. Fiala, BS, Brandon B. Wang, Mark A. Schroeder, MD, Tanya M. Wildes, MD MSCI, Armin Ghobadi, MD, Keith E. Stockerl-Goldstein, MD, Ravi Vij, MBBS

Blood (2018) 132 (Supplement 1): 5627.

https://doi.org/10.1182/blood-2018-99-112258

Published: 2018

Journal Articles

Disparities in Healthcare Resource Utilization for Multiple Myeloma

Mark A. Fiala, BS, Tanya M. Wildes, MD MSCI, Mark A. Schroeder, MD, Armin Ghobadi, MD, Keith E. Stockerl-Goldstein, MD, Ravi Vij, MBBS

Blood (2018) 132 (Supplement 1): 4793.

https://doi.org/10.1182/blood-2018-99-118392

Published: 2018

Journal Articles

A Study of Tbo-Filgrastim (Granix) to Disrupt the Bone Marrow Microenvironment in Patients with Multiple Myeloma Undergoing Autologous Stem Cell Transplantation

Meagan Jacoby, MD, Reetom Bera, Theresa Fletcher, Mark A. Fiala, BS, Kathryn Trinkaus, PhD, John F. DiPersio, MD PhD, Keith E. Stockerl-Goldstein, MD, Mark A. Schroeder, MD, Daniel C. Link, MD, Ravi Vij, MBBS

Blood (2018) 132 (Supplement 1): 2146.

https://doi.org/10.1182/blood-2018-99-115603

Published: 2018

Journal Articles

D.C.E.P. in Patients with Quad- or Penta-Refractory Multiple Myeloma

Scott Goldsmith, MD, Mark A. Fiala, BS, Brandon B. Wang, Mark A. Schroeder, MD, Tanya M. Wildes, MD MSCI, Armin Ghobadi, MD, Keith E. Stockerl-Goldstein, MD, Ravi Vij, MBBS

Blood (2018) 132 (Supplement 1): 2021.

https://doi.org/10.1182/blood-2018-99-117713

Published: 2018

Journal Articles

Selinexor in Combination with Cladribine, Cytarabine and G-CSF for Relapsed or Refractory AML

Geoffrey L. Uy, MD, Michael P Rettig, PhD, Theresa Fletcher, Peter A Riedell, MD, Keith E. Stockerl-Goldstein, MD, Armin Ghobadi, MD, Meagan Jacoby, MD PhD, Amanda F. Cashen, MD, Rizwan Romee, MD, Iskra Pusic, MD, Camille N. Abboud, MD, Mark A. Schroeder, MD, Ravi Vij, MDMBA, Peter Westervelt, MDPhD, John F DiPersio, MD PhD

Blood (2017) 130 (Supplement 1): 816.

https://doi.org/10.1182/blood.V130.Suppl_1.816.816

Published: 2017

Journal Articles

A Cost-Benefit Analysis of Bortezomib, Lenalidomide, and Bortezomib/Lenalidomide Combination Therapy for Newly Diagnosed Multiple Myeloma

Mark A. Fiala, BS, Tanya M. Wildes, MDMSCI, Gunjan L. Shah, MD, Armin Ghobadi, MD, Mark A. Schroeder, MD, Keith E. Stockerl-Goldstein, MD, Ravi Vij, MDMBA

Blood (2017) 130 (Supplement 1): 3108.

https://doi.org/10.1182/blood.V130.Suppl_1.3108.3108

Published: 2017

Journal Articles

Statin Use Is Associated with Decreased Mortality in Multiple Myeloma— a SEER Medicare Study

Shivaprasad Manjappa, MD, Mark A. Fiala, BS, Pavan Kumar Bhamidipati, MBBS, MD, Keith E. Stockerl-Goldstein, MD, Mark A. Schroeder, MD, Armin Ghobadi, MD, Ravi Vij, MDMBA, Tanya M. Wildes, MDMSCI

Blood (2017) 130 (Supplement 1): 1860.

https://doi.org/10.1182/blood.V130.Suppl_1.1860.1860

Published: 2017

Journal Articles

Overexpression of EZH2 in Multiple Myeloma Is Associated with Poor Prognosis Regardless of Treatment with Novel Agents or High-Dose Chemotherapy

Mark A. Schroeder, MD, Mark A. Fiala, BS, Armin Ghobadi, MD, Keith E. Stockerl-Goldstein, MD, Tanya M. Wildes, MDMSCI, Ravi Vij, MDMBA

Blood (2017) 130 (Supplement 1): 4335.

https://doi.org/10.1182/blood.V130.Suppl_1.4335.4335

Published: 2017

Journal Articles

A Phase I Study of Carfilzomib and Pegylated Liposomal Doxorubicin for Relapsed or Refractory Multiple Myeloma

Jesse Keller, MD, Mark A Fiala, BS, CCRP, Jeevan Sekhar, Connie Ceriotti, Melissa Allen, Camille N. Abboud, MD, Keith E. Stockerl-Goldstein, MD, Tanya M Wildes, MD MSCI, Michael H. Tomasson, MD, Ravi Vij, MBBS, MD

Blood (2014) 124 (21): 4731.

https://doi.org/10.1182/blood.V124.21.4731.4731

Published: 2014

Journal Articles

Ibrutinib, Single Agent or in Combination with Dexamethasone, in Patients with Relapsed or Relapsed/Refractory Multiple Myeloma (MM): Preliminary Phase 2 Results

Ravi Vij, MBBS, MD, Carol Ann Huff, MD, William I. Bensinger, MD, David S. Siegel, MD PhD, Sundar Jagannath, MD, Jesus Berdeja, MD, Nikoletta Lendvai, MD PhD, Daniel Lebovic, MD, Larry D. Anderson, MD PhD, Caitlin L. Costello, MD, Keith E. Stockerl-Goldstein, MD, Jacob P. Laubach, MD, Laurence Elias, MD, Fong Clow, ScD, Maria Fardis, PhD MBA, Thorsten Graef, MD PhD, Elizabeth Bilotti, MSN, Paul G. Richardson

Blood (2014) 124 (21): 31.

https://doi.org/10.1182/blood.V124.21.31.31

Published: 2014

Journal Articles

Acute Myeloid Leukemia Patients with Pre-Transplant Ablated Marrows Have Similar Rates of Survival and Relapse Compared to Patients in Complete Remission after Allogeneic Hematopoietic Cell Transplantation

Khoan Vu, MD, Shivaprasad Manjappa, MD, John F. DiPersio, MD PhD, Feng Gao, PhD, Peter Westervelt, MD PhD, Ravi Vij, MBBS, MD, Keith E. Stockerl-Goldstein, MD, Geoffrey L. Uy, MD, Camille N. Abboud, MD, Mark A. Schroeder, MD, Amanda F. Cashen, MD, Rizwan Romee, MD

Blood (2014) 124 (21): 2557.

https://doi.org/10.1182/blood.V124.21.2557.2557

Published: 2014

Journal Articles

Treatment Advances for Multiple Myeloma Have Disproportionally Benefited Patients Who Are Young, White, and Have Higher Socioeconomic Status

Mark A. Fiala, BS, CCRP, Jesse Keller, MD, Keith E. Stockerl-Goldstein, MD, Michael H. Tomasson, MD, Ravi Vij, MBBS, MD, Tanya M Wildes, MD MSCI

Blood (2014) 124 (21): 555.

https://doi.org/10.1182/blood.V124.21.555.555

Published: 2014

NARROW

A Single Center Retrospective Analysis of Daratumumab, Pomalidomide, and Dexamethasone As a Second Line Therapy for Multiple Myeloma

Severity of Sars-Cov-2 Infection in Patients with Hematologic Malignancies: A COVID-19 and Cancer Consortium (CCC19) Registry Analysis

Preliminary Results from a Phase 1b Study of TAK-079, an Investigational Anti-CD38 Monoclonal Antibody (mAb) in Patients with Relapsed/ Refractory Multiple Myeloma (RRMM)

The Ire of IRE1α: Overexpression of IRE1α at Myeloma Diagnosis Is Associated with Decreased Survival While Downregulation of IRE1α Expression Is Predictive of Therapy Resistance

Utilization of Autologous Stem Cell Transplantation in Older Patients with Newly Diagnosed Multiple Myeloma

The Characteristics, Treatment Patterns, and Outcomes of Older Adults with Multiple Myeloma

The Effect of Maintenance Therapy Following Salvage Autologous Stem Cell Transplant in Multiple Myeloma Patients

Increasing Daratumumab Frequency As a Way to Restore Responses- a Retrospective Case Study

Bendamustine in Patients with Quad- and Penta-Refractory Multiple Myeloma

Disparities in Healthcare Resource Utilization for Multiple Myeloma

A Study of Tbo-Filgrastim (Granix) to Disrupt the Bone Marrow Microenvironment in Patients with Multiple Myeloma Undergoing Autologous Stem Cell Transplantation

D.C.E.P. in Patients with Quad- or Penta-Refractory Multiple Myeloma

Selinexor in Combination with Cladribine, Cytarabine and G-CSF for Relapsed or Refractory AML

A Cost-Benefit Analysis of Bortezomib, Lenalidomide, and Bortezomib/Lenalidomide Combination Therapy for Newly Diagnosed Multiple Myeloma

Statin Use Is Associated with Decreased Mortality in Multiple Myeloma— a SEER Medicare Study

Overexpression of EZH2 in Multiple Myeloma Is Associated with Poor Prognosis Regardless of Treatment with Novel Agents or High-Dose Chemotherapy

A Phase I Study of Carfilzomib and Pegylated Liposomal Doxorubicin for Relapsed or Refractory Multiple Myeloma

Ibrutinib, Single Agent or in Combination with Dexamethasone, in Patients with Relapsed or Relapsed/Refractory Multiple Myeloma (MM): Preliminary Phase 2 Results

Acute Myeloid Leukemia Patients with Pre-Transplant Ablated Marrows Have Similar Rates of Survival and Relapse Compared to Patients in Complete Remission after Allogeneic Hematopoietic Cell Transplantation

Treatment Advances for Multiple Myeloma Have Disproportionally Benefited Patients Who Are Young, White, and Have Higher Socioeconomic Status

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only